Goldman Sachs’s Enzymotec Ltd ENZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-46,046
| Closed | -$546K | – | 6694 |
|
|
2017
Q4 | $546K | Buy |
+46,046
| New | +$534K | ﹤0.01% | 4755 |
|
|
2017
Q1 | – | Sell |
-158,803
| Closed | -$1.04M | – | 7174 |
|
|
2016
Q4 | $1.04M | Sell |
158,803
-757,805
| -83% | -$4.99M | ﹤0.01% | 4418 |
|
|
2016
Q3 | $6.42M | Sell |
916,608
-216,606
| -19% | -$1.74M | ﹤0.01% | 2833 |
|
|
2016
Q2 | $9.47M | Buy |
1,133,214
+200,459
| +21% | +$1.66M | ﹤0.01% | 2358 |
|
|
2016
Q1 | $8.42M | Sell |
932,755
-36,272
| -4% | -$316K | ﹤0.01% | 2356 |
|
|
2015
Q4 | $9.5M | Buy |
969,027
+21,304
| +2% | +$202K | ﹤0.01% | 2292 |
|
|
2015
Q3 | $8.58M | Buy |
947,723
+222,111
| +31% | +$1.98M | ﹤0.01% | 2378 |
|
|
2015
Q2 | $6.06M | Buy |
725,612
+637,281
| +721% | +$5.85M | ﹤0.01% | 2799 |
|
|
2015
Q1 | $636K | Buy |
88,331
+56,647
| +179% | +$401K | ﹤0.01% | 4901 |
|
|
2014
Q4 | $242K | Sell |
31,684
-4,887
| -13% | -$35.5K | ﹤0.01% | 5997 |
|
|
2014
Q3 | $244K | Sell |
36,571
-13,798
| -27% | -$149K | ﹤0.01% | 5969 |
|
|
2014
Q2 | $684K | Sell |
50,369
-651
| -1% | -$10.9K | ﹤0.01% | 5044 |
|
|
2014
Q1 | $1.12M | Sell |
51,020
-13,231
| -21% | -$351K | ﹤0.01% | 4565 |
|
|
2013
Q4 | $1.74M | Buy |
+64,251
| New | +$1.53M | ﹤0.01% | 4227 |
|
Goldman Sachs's ENZY Position: Q1 2018 in Review
Goldman Sachs sold out of Enzymotec Ltd (ENZY) in Q1 2018, closing a stake of 46,046 shares — an estimated $546K sold.
Goldman Sachs first reported a position in ENZY in Q4 2013 and held it in 14 quarters. The position peaked at $9.5M in Q4 2015. 0 funds tracked by Wall St. Rank hold ENZY as of Q1 2018.
- Goldman Sachs reported no remaining Enzymotec Ltd position as of Q1 2018 after selling out during the quarter.
- Goldman Sachs sold 46,046 Enzymotec Ltd shares in Q1 2018, an estimated $546K.
- Goldman Sachs first reported a position in Enzymotec Ltd in Q4 2013 and held it in 14 quarters.
- Goldman Sachs's Enzymotec Ltd position peaked at $9.5M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q1 2018.
Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.